Garden Health (GH) Q1 2026: Screening Gross Margin Triples to 56% as Shield Volumes Accelerate
Garden Health’s Q1 marked a pivotal inflection as Shield screening margins surged on volume and pricing gains, while oncology and data businesses sustained robust growth. Commercial momentum from Shield’s direct-to-consumer and Quest launches fueled upside in both volume and profitability, prompting a raised full-year outlook. Management’s discipline in reinvestment and expanding AI-driven product depth positions the company for continued share gains across oncology and multi-cancer screening.
Summary
- Screening Margin Expansion: Shield’s cost reductions and ASP gains drove a step-change in screening profitability.
- Oncology Platform Depth: Smart platform and AI apps extended Garden360 and Reveal adoption, broadening clinical utility.
- Guidance Raised: Upgraded revenue and volume outlook reflects commercial traction and pipeline visibility.
Business Overview
Garden Health is a precision oncology and cancer screening company that provides genomic and epigenomic testing solutions. The company monetizes through three primary segments: oncology (therapy selection and monitoring), biopharma and data (companion diagnostics and real-world evidence), and screening (notably, the Shield blood test for colorectal and multi-cancer detection). Revenue is generated from test sales to healthcare providers, biopharma partnerships, and direct-to-consumer channels.
Performance Analysis
Q1 2026 delivered broad-based acceleration across Garden Health’s portfolio, with total revenue up 48% year-over-year and all segments contributing to the upside. Oncology, the company’s largest business, posted 36% revenue growth and 47% volume growth, reflecting both increased adoption and new product traction—notably, Garden360 Liquid and Tissue, and the fast-scaling Reveal MRD test.
Screening emerged as the quarter’s standout, with Shield revenue and volume both up sharply from the prior year, propelled by successful direct-to-consumer (DTC) and healthcare provider campaigns, as well as the nationwide Quest Diagnostics partnership. Gross margin for screening leapt from 18% to 56% year-over-year, driven by higher average selling prices (ASP) after Medicare rate resets and disciplined cost reduction, including sequencing and lab workflow efficiencies. Biopharma and data grew 17%, supported by new companion diagnostic (CDX) approvals and deepening pharma partnerships.
- Screening Margin Inflection: Shield’s non-GAAP cost per test dropped to $420, with a path to $200 at scale, underpinning profitability upside.
- Oncology Volume Strength: Garden360 Liquid and Tissue both outpaced market growth, fueled by Infinity AI-enabled smart apps and clinical adoption.
- Reveal Momentum: Over 100% volume growth in Reveal, now expanding into therapy monitoring and multiple tumor types, sets up future ASP catalysts.
Operating expenses rose 34%, primarily from increased sales and marketing to support Shield’s expansion, but were offset by higher gross profit and cash discipline. Free cash flow burn remains a focus, with the company reiterating full-year improvement and a target for breakeven by end of 2027.
Executive Commentary
"Our commercial flywheel has achieved a new level of velocity, delivering our fastest year-over-year percentage revenue growth in the last five years and surpassing the $1 billion trailing 12-month revenue milestone. This is a testament to the burgeoning scale and long-term durability of our business."
Helmi El-Tiki, Co-CEO
"Non-GAAP gross margin was 66% in Q1, up from 65% in the prior year period. The improvement was primarily driven by lower Garden360 liquid cost per test, reflecting the ongoing transition to NovaSeqX, which will be completed in May, 2026."
Mike Bell, Chief Financial Officer
Strategic Positioning
1. Shield Screening: Commercial Scale and Margin Leverage
Shield’s rapid volume growth and ASP uplift are direct results of targeted DTC campaigns, the Quest Diagnostics rollout, and high physician adherence rates. With >90% adherence, Shield is positioned as the only FDA-approved blood-based CRC screening with Medicare coverage, and its expansion into multi-cancer detection (MCD) and Asia via Manulife opens new TAM (total addressable market).
2. Oncology Platform: AI-Driven Smart Apps and Portfolio Synergy
The Garden360 and Reveal platforms are compounding adoption through Infinity AI-powered clinical applications, enabling deeper penetration across therapy selection, MRD, and therapy monitoring. The company’s large and growing data repository underpins new product development and biopharma partnerships, creating a defensible data moat.
3. Biopharma and Data: Strategic CDX and Pharma Collaborations
Biopharma and data revenue continues to diversify, with 26 CDX approvals across major markets and recent multi-year agreements with Merck and others. Infinity AI-generated real-world evidence is now supporting regulatory submissions and tumor-agnostic approvals, reinforcing Garden’s value proposition to pharma partners.
4. Operational Discipline: Cost Control and Cash Burn Trajectory
Despite heavy investment in Shield commercialization, Garden Health maintained gross margin expansion and reiterated its commitment to positive free cash flow (ex-screening) in 2026 and company-wide breakeven in 2027. Sequencing cost reductions (NovaSeqX) and lab automation are key levers for further margin improvement.
5. Pipeline and Regulatory Catalysts
Multiple near-term catalysts are in play: FDA approval for Garden360 Liquid, Reveal Ultra launch, and MoldDx reimbursement decisions for Reveal in breast and therapy monitoring. Inclusion in ACS screening guidelines and further Shield ASP improvement remain sources of upside.
Key Considerations
This quarter’s results highlight Garden Health’s ability to drive simultaneous growth, margin expansion, and pipeline advancement across multiple business lines. The company’s scale and data advantage are increasingly evident in both oncology and screening, while disciplined reinvestment supports long-term share gains.
Key Considerations:
- Shield’s Adherence and Commercial Reach: High patient adherence and EMR integrations are accelerating Shield’s penetration into new provider accounts.
- AI Differentiation: Infinity AI is translating data scale into actionable clinical insights, supporting both commercial and biopharma traction.
- Cross-Sell and Platform Synergy: Multi-product ordering among physicians is rising, deepening customer relationships and boosting LTV (lifetime value).
- Reimbursement and ASP Leverage: Upcoming MoldDx and ACS guideline decisions could unlock incremental revenue and margin for Reveal and Shield, respectively.
- Sales Force Expansion: Incremental gross profit is being reinvested in commercial infrastructure, with a focus on sales rep productivity and quality.
Risks
Key risks center on reimbursement timing, ASP compression as commercial Shield volumes rise, and execution on scaling sales and lab operations. Regulatory outcomes (FDA, MoldDx, ACS) could materially shift revenue trajectories, while competitive intensity from large diagnostics and pharma entrants may pressure share gains and pricing. Management’s raised guidance reflects confidence but also elevates execution expectations in a rapidly evolving market.
Forward Outlook
For Q2 2026, Garden Health guided to:
- Continued sequential Shield volume growth, with >10,000 incremental tests per quarter implied in the guide
- Stable Shield ASP in the $775 range for the remainder of the year, reflecting a gradual mix shift toward commercial patients
For full-year 2026, management raised guidance:
- Total revenue of $1.30 to $1.32 billion (32% to 34% growth)
- Oncology revenue growth of 28% to 29%, >35% volume growth
- Screening revenue of $186 to $198 million, driven by Shield
- Non-GAAP gross margin of 64% to 65%
- Free cash flow burn of $185 to $195 million, with ex-screening business to be positive in 2026
Management highlighted:
- Multiple product launches and regulatory milestones expected in 2026
- Potential upside from ACS guideline inclusion and FDA approvals not yet in guidance
Takeaways
Garden Health’s Q1 2026 performance demonstrates accelerating commercial momentum, margin expansion, and pipeline advancement, all underpinned by AI-driven product innovation and disciplined reinvestment.
- Screening Margin Step-Change: Shield’s cost and price leverage fundamentally improved screening economics, validating the commercial model and supporting reinvestment in growth.
- Oncology Platform Depth: Smart apps, AI, and a growing data treasury are enabling Garden to extend its lead in oncology testing and biopharma partnerships.
- Watch for Regulatory Catalysts: FDA, MoldDx, and ACS decisions in the coming quarters could unlock further upside and cement Garden’s leadership in precision oncology and screening.
Conclusion
Garden Health enters the remainder of 2026 with visible momentum, a robust pipeline, and multiple avenues for upside. Execution on Shield scale, oncology innovation, and reimbursement milestones will determine the trajectory of sustainable growth and profitability.
Industry Read-Through
Garden Health’s Q1 signals an industry-wide inflection in blood-based cancer screening and AI-driven oncology diagnostics. The Shield ASP reset and rapid margin expansion set a new bar for profitability in screening, while the success of DTC and EMR integration highlight the importance of omnichannel commercial models. Competitors must accelerate AI deployment, data aggregation, and commercial scale to keep pace, especially as biopharma partners demand actionable real-world evidence and regulatory bodies raise the bar for clinical utility. Reimbursement and guideline inclusion remain critical levers for all players in the precision diagnostics space.